Allopurinol, gout, and cardiovascular risk - Top-Institutions - MDSpire

Allopurinol, gout, and cardiovascular risk

  • By

  • Jalina Jannink

  • Arend Mosterd

  • Aernoud T L Fiolet

  • October 29, 2025

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Rheumatology
    • Cardiology
    • Clinical Pharmacology

  • #2

    University of Oxford
    University of Oxford

    Oxford, England

    Key Differentiators

    • Epidemiology
    • Rheumatology
    • Cardiovascular Medicine

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Rheumatology
    • Cardiology

  • #4

    University of Amsterdam
    University of Amsterdam

    Amsterdam, Netherlands

    Key Differentiators

    • Pharmaco-epidemiology
    • Rheumatology

Original Source(s)

Allopurinol, gout, and cardiovascular risk

  • by Jalina Jannink, Arend Mosterd, Aernoud T L Fiolet

  • October 29, 2025

Related Content

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Changes in Serum Urate Levels after Bariatric Surgery in Patients with Obesity: An Observational Study